Jump to Navigation
Home ›

R. Andrew Sewell, MD

Printer-friendly version
Associate research scientist, VA Connecticut Healthcare, Yale University School of Medicine
Disclosure

Latuda: “Procognitive” or Pro-Profit? [Subscribers Only]

Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?

Latuda: “Procognitive” or Pro-Profit? [Free Article]

Source: 
TCPR, June 2011, Vol 9, Issue 6, Schizophrenia

Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?

Click here to view mobile site

Current Issue

Antidepressant Roundup 2012

May, 2012
Vol: 10 Issue: 5
Read More
Previous Issues

Topics

ADHD
Antidepressants
Antipsychotics
Anxiety Disorder
Benzodiazepines
Bipolar Disorder
Brain Devices
Child Psychiatry
Cognitive Behavioral Therapy
Computers in Psychiatric Practice
Cultural Competence
Dementia
Depressive Disorder
Diagnostic Testing
Eating Disorders
Gender & Sexuality
Genetics and Psychiatry
Health Care Policy
HIPAA
Hypnotics
Laboratory Testing in Psychiatry
Mood Stabilizers
Natural Medications
Neuroscience in Psychiatry
Novel Anticonvulsants
OCD
Personality Disorders
Pharmaceutical Industry
Practice Tools and Tips
Psychopharmacology Tips
Psychotherapy
PTSD
Research Updates
Seasonal Affective Disorder
Sexual Dysfunction
Sleep Disorders
Smoking Cessation Agents
Substance Abuse
Understanding Psychiatric Research
Weight Loss Medications
Women's Issues in Psychiatry
Printer-friendly version
Medication Fact Sheets

Search

Follow Us

The Carlat Report Twitter Feed
Carlat Report RSS
The Carlat Report Blog
The Carlat Report Fan Page

Editor-in-Chief

After 10 years at the helm of TCPR, Dr. Carlat has handed over editor-in-chief duties to Dr. Steve Balt. We’re excited to welcome him aboard! Read More...

The 2012 Carlat Atypical Antipsychotics Table is Now Available!

With all the atypicals on the market, it's hard to keep track of indications, dosages, and all the other relevant facts for each drug. Use this table for summaries on these meds, their uses, their side effects, and a whole slew of other information.

See the Atypical Antipsychotics table!